Jun Han

Title: **The Innovative Journey of Inventor Jun Han**

Introduction

Jun Han, an accomplished inventor based in Tianjin, China, has made significant contributions to the field of biopharmaceuticals. Known for his pioneering work, Han has been granted one patent that showcases his innovative approach to treating complex medical conditions.

Latest Patents

Han's most notable patent is titled "Method of treating NASH using a long-acting mutant human fibroblast growth factor." This invention pertains to a method of treatment that involves administering a long-acting mutant human fibroblast growth factor to subjects in need. The specific compound noted in his patent is mPEG-CH—NH-mFGF21, with mFGF21 consisting of SEQ ID NO: 1. This groundbreaking method addresses non-alcoholic steatohepatitis (NASH), highlighting Han’s impact on advancing therapeutic strategies for liver diseases.

Career Highlights

Jun Han is affiliated with Tasly Biopharmaceuticals Co., Ltd., a company recognized for its commitment to innovation in the healthcare sector. His work there has not only contributed to his patent portfolio but has also elevated the company's position in biopharmaceutical research and development.

Collaborations

Throughout his career, Han has collaborated with esteemed colleagues such as Jian Li and Xiaohui Ma. These partnerships have further fostered an environment of creativity and innovation, leading to new discoveries and advances in treatment methodologies.

Conclusion

Jun Han exemplifies the spirit of innovation in the biopharmaceutical industry. Through his patent, he is paving the way for new treatments for NASH, demonstrating the critical role inventors play in medical advancements. As he continues his work at Tasly Biopharmaceuticals Co., Ltd., the contributions of Jun Han are certain to leave a lasting impact on healthcare and improve patient outcomes worldwide.